AGEAS


Surprising Non-Life and turmoiled Asia

12/05/22 -"Ageas’ Q1 22 results yielded mixed feelings. On the one hand, P&C has been surprisingly good but could revert to lower levels, we believe. On the other hand, Asia has been disappointing and could ..."

Pages
45
Language
English
Published on
12/05/22
You may also be interested by these reports :
24/05/22
Buying into Scor (Add, France) amounted buying into Dennis Kessler’s vision. The CEO is now Chairman, still too influential but the exit is closer. ...

24/05/22
Our target price is slightly downgraded as we integrate the Q1 22 figures into our model. Most of the downgrade is driven by the EPS cut for FY 22 ...

19/05/22
Strong Q1 22 results posted by Generali. Both Life and Non-life have disclosed strong performances top-line wise and in terms of profitability ...

18/05/22
Aviva’s Q1 22 trading update was slightly above our expectations although this remains very much tied to the top-line and profitability could be ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO